In Brief
Refine Search
Pharmaceutical
UK-based immunotherapy firm Centauri Therapeutics has secured a £1 million ($1.25 million) grant from PACE (Pathways to Antimicrobial Clinical Efficacy) to further develop its Alphamer technology. 25 November 2024
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Biotechnology
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
Pharmaceutical
The US Food and Drug Administration (FDA) has approved Lonsurf (trifluridine/tipiracil), developed by Taiho Oncology Inc and Taiho Pharmaceutical, subsidiaries of Japanese drugmaker Otsuka Holdings, with the decision coming ahead of the August 13 expected date. 3 August 2023
Biotechnology
Privately-held USA-based CG Oncology, previously known as Cold Genesys, has announced the closing of an oversubscribed $105 million crossover financing round. 3 August 2023
Biosimilars
South Korea’s Samsung Bioepis and USA-based Organon have announced the interchangeable result of its Humira (adalimumab) biosimilar, SB5, based on a recently conducted Phase IV study. 3 August 2023
Biotechnology
US precision genetic rare diseases specialist Sarepta Therapeutics yesterday reported financial results for the second quarter 2023. 3 August 2023
Biotechnology
Switzerland-based biologics contract development and manufacturing organization (CDMO), Celonic Group has appointed Dr Samantha Cimitan as chief executive. 3 August 2023
Generics
Israeli generics giant Teva Pharmaceutical Industries made stock market gains of around 12% during Wednesday morning’s trading. 2 August 2023
Biotechnology
Japanese companies have been slow to progress COVID-19 vaccines, but today Daiichi Sankyo announced that it has received approval for the manufacturing and marketing of Daichirona for Intramuscular Injection (DS-5670). 2 August 2023
Biotechnology
US biotech Seagen, the subject of a $43 billion takeover by US pharma giant Pfizer, today reported financial results for the second quarter ended June 30, 2023, highlighting record net product sales, with significant year-over-year growth of 26% to $544 million 2 August 2023
Biotechnology
The UK's National Institute for Health and Care Excellence (NICE) has issued a draft Appraisal Consultation Document recommending against CSL Behring’s Hemgenix (etranacogene dezaparvovec) for severe and moderately severe hemophilia B (congenital factor IX deficiency) patients without a history of Factor IX (FIX) inhibitors. 2 August 2023
Pharmaceutical
German family-owned drugmaker Grünenthal and Japan’s Kyowa Kiron today announced the successful completion of a deal to enter into a joint venture collaboration for Kyowa Kirin International's established medicines portfolio. 2 August 2023
Biosimilars
The end of exclusivity for AbbVie’s top-selling biologic Humira (adalimumab) has provided a key test of whether biosimilars are finally ready to deliver on their promise in the US biopharmaceutical market. 2 August 2023
Biotechnology
Dutch rare diseases biotech firm ProQR Therapeutics saw its shares rise 5% to $1.58 yesterday, after it announced an agreement to divest its late-stage ophthalmic assets, sepofarsen and ultevursen, to Laboratoires Théa. 2 August 2023
Pharmaceutical
Shares of UK clinical stage drug development company Evgen Pharma (AIM: EVG) were down more than 8% at 2.94 pence mid-morning, after it revealed that JuvLife Ltd, a division of Juvenescence, has terminated the patent and know-how license agreement for Evgen's Sulforadex sulforaphane stabilization technology. 2 August 2023
Pharmaceutical
US biopharma company Vertex Pharmaceuticals has reported consolidated financial results for the second quarter ended June 30, 2023 and updated its full year 2023 financial guidance. 2 August 2023
Biotechnology
US drugmaker EQRx, founded on the principle of developing and delivering innovative medicines to patients at radically lower prices, saw its share price leap more than 19% to $2.04 by mid-morning (having hit a high of $2.22), on news of a takeover bid. 1 August 2023
Pharmaceutical
While its work on the novel coronavirus swept Pfizer to the top of the world’s largest drugmakers by revenue, the firm must now find a way to manage a precipitous drop in sales, as countries move past the acute phase of the pandemic. 1 August 2023
Pharmaceutical
US pharma giant Merck & Co today announced financial results for the second quarter of 2023 that topped expectations on strong sales of its blockbuster cancer drug Keytruda (pembrolizumab) and HPV vaccine Gardasil. 1 August 2023
Pharmaceutical
Bimervax, the COVID-19 vaccine developed by Spanish company HIPRA Human Health, has today been authorized by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). 1 August 2023
Pharmaceutical
Belgian women’s healthcare company Mithra Pharmaceuticals saw its shares gain 13.9% to 1.96 euros, after it revealed it has signed licensing agreement with privately-held Canadian specialty pharma firm Searchlight Pharma for the Canadian rights to Donesta. 1 August 2023
Pharmaceutical
Age-related and autoimmune disease specialist MyMD Pharmaceuticals has announced positive Phase II data for its oral TNF-α inhibitor, MYMD-1. 1 August 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze